The biotech industry is seeing a massive increase in the amount of funding available to early-stage research. At Bio Europe Spring, we spoke to Nerida Scott, VP of New Ventures and Transactions at Johnson & Johnson Innovation, to learn more about what’s behind it.
In the last five years, the total invested in seed and Series A fundraisings of biotech companies has doubled to reach over €3Bn per year. A particularly big difference can be seen within the European biotech ecosystem.
